Kymera Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

KYMR$136.64-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

For the three and six months ended June 30, 2026 and 2025

(In thousands, except for share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2026	2025	2026	2025
Collaboration revenue	$65,000	$11,476	$99,365	$33,576
Operating expenses:
Research and development	$119,481	$78,388	$217,644	$158,643
General and administrative	21,126	17,645	41,484	33,916
Total operating expenses	140,607	96,033	259,128	192,559
Loss from operations	(75,607)	(84,557)	(159,763)	(158,983)
Other income (expense):
Interest and other income	14,477	8,051	29,459	16,968
Interest and other expense	(81)	(108)	(141)	(180)
Total other income:	14,396	7,943	29,318	16,788
Net loss	$(61,211)	$(76,614)	$(130,445)	$(142,195)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities	(2,963)	337	(8,957)	1,764
Total comprehensive loss	$(64,174)	$(76,277)	$(139,402)	$(140,431)
Net loss	$(61,211)	$(76,614)	$(130,445)	$(142,195)
Net loss per share, basic and diluted	$(0.62)	$(0.95)	$(1.33)	$(1.77)
Weighted average common stock outstanding, basic and diluted	98,177,158	80,449,405	97,857,489	80,298,940

CONDENSED CONSOLIDATED STATEMENTS OF

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.